Huang Zhi-Mei, Pan Chang-Chuan, Wu Pei-Hong, Zhao Ming, Li Wang, Huang Zi-Lin, Yi Rui-Yang
Division of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
Chin J Cancer. 2013 Jun;32(6):334-41. doi: 10.5732/cjc.012.10093. Epub 2012 Sep 10.
For patients with unresectable pancreatic cancer, current chemotherapies have negligible survival benefits. Thus, developing effective minimally invasive therapies is currently underway. This study was conducted to evaluate the efficacy of transarterial chemoembolization plus radiofrequency ablation and/or 125I radioactive seed implantation on unresectable pancreatic cancer. We analyzed the outcome of 71 patients with unresectable pancreatic carcinoma who underwent chemoembolization plus radiofrequency ablation and/or radioactive seed implantation. Of the 71 patients, the median survival was 11 months, and the 1-, 2-, and 3-year overall survival rates were 32.4%, 9.9%, and 6.6%, respectively. Patients who had no metastasis, who had oligonodular liver metastases (≤3 lesions), and who had multinodular liver metastases (>3 lesions) had median survival of 12, 18, and 8 months, respectively, and 1-year overall survival rates of 50.0%, 68.8%, and 5.7%, respectively. Although the survival of patients without liver metastases was worse than that of patients with oligonodular liver metastasis, the result was not significant (P = 0.239). In contrast, the metastasis-negative patients had significantly better survival than did patients with multinodular liver metastases (P < 0.001). Patients with oligonodular liver lesions had a significant longer median survival than did patients with multinodular lesions (P < 0.001). In conclusion, combined minimally invasive therapies had good efficacy on unresectable pancreatic cancer and resulted in a good control of liver metastases. In addition, the number of liver metastases was a significant factor in predicting prognosis and response to treatment.
对于无法切除的胰腺癌患者，目前的化疗对生存期的益处微乎其微。因此，目前正在开展有效的微创治疗方法。本研究旨在评估经动脉化疗栓塞联合射频消融和/或碘-125放射性粒子植入治疗无法切除胰腺癌的疗效。我们分析了71例接受化疗栓塞联合射频消融和/或放射性粒子植入的无法切除胰腺癌患者的治疗结果。71例患者的中位生存期为11个月，1年、2年和3年总生存率分别为32.4%、9.9%和6.6%。无转移、寡结节性肝转移（≤3个病灶）和多结节性肝转移（>3个病灶）的患者中位生存期分别为12个月、18个月和8个月，1年总生存率分别为50.0%、68.8%和5.7%。虽然无肝转移患者的生存期比寡结节性肝转移患者差，但差异无统计学意义（P = 0.239）。相反，无转移患者的生存期明显优于多结节性肝转移患者（P < 0.001）。寡结节性肝病灶患者的中位生存期明显长于多结节性病灶患者（P < 0.001）。总之，联合微创治疗对无法切除的胰腺癌疗效良好，能有效控制肝转移。此外，肝转移灶数量是预测预后和治疗反应的重要因素。
